H.C. Wainwright lowered the firm’s price target on Sage Therapeutics to $25 from $28 and keeps a Neutral rating on the shares. The firm came away from Sage’s Q1 results encouraged by the early uptake for Zurzuvae with sales well above its expectations. However, the firm is taking a more conservative stance on dalzanemdor following failure in the PRECEDENT study, despite the early traction for Zurzuvae being a positive, the analyst tells investors in a post-earnings note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics reports Q1 EPS ($1.80), consensus ($1.65)
- Biotech Alert: Searches spiking for these stocks today
- SAGE Therapeutics Adjusts Inducement Equity Plan and Sets End Date
- Sage Therapeutics price target lowered to $19 from $34 at Scotiabank
- Sage Therapeutics price target lowered to $17 from $25 at Oppenheimer